Prelude Therapeutics Incorporated (NASDAQ:PRLD - Get Free Report) CEO Krishna Vaddi acquired 100,000 shares of Prelude Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was bought at an average price of $0.93 per share, with a total value of $93,000.00. Following the purchase, the chief executive officer now directly owns 1,167,275 shares of the company's stock, valued at approximately $1,085,565.75. This trade represents a 9.37 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
PRLD traded up $0.32 during midday trading on Friday, reaching $1.21. 2,843,192 shares of the company's stock were exchanged, compared to its average volume of 198,793. Prelude Therapeutics Incorporated has a 1-year low of $0.80 and a 1-year high of $6.80. The stock has a market capitalization of $66.32 million, a PE ratio of -0.68 and a beta of 1.49. The business's 50-day moving average price is $1.22 and its 200 day moving average price is $3.19.
Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. The company had revenue of $3.00 million for the quarter. As a group, analysts expect that Prelude Therapeutics Incorporated will post -1.81 EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. boosted its stake in shares of Prelude Therapeutics by 885.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company's stock worth $362,000 after purchasing an additional 157,218 shares during the last quarter. State Street Corp lifted its stake in shares of Prelude Therapeutics by 35.1% during the third quarter. State Street Corp now owns 286,046 shares of the company's stock valued at $592,000 after buying an additional 74,300 shares during the period. Walleye Capital LLC boosted its position in Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company's stock worth $172,000 after acquiring an additional 67,946 shares during the last quarter. XTX Topco Ltd purchased a new stake in Prelude Therapeutics in the 3rd quarter worth approximately $100,000. Finally, Geode Capital Management LLC raised its holdings in Prelude Therapeutics by 8.2% in the 3rd quarter. Geode Capital Management LLC now owns 391,716 shares of the company's stock valued at $811,000 after acquiring an additional 29,765 shares during the last quarter. Institutional investors and hedge funds own 79.72% of the company's stock.
A number of equities research analysts have recently issued reports on PRLD shares. JMP Securities reiterated a "market outperform" rating and set a $4.00 price target (down from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Prelude Therapeutics in a report on Friday, November 8th.
Check Out Our Latest Stock Analysis on Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Prelude Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prelude Therapeutics wasn't on the list.
While Prelude Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.